This document is an investor presentation for NEMUS Bioscience, an OTCQB-listed biotech company developing cannabinoid-based therapies. Some key points: - NEMUS has a proprietary pipeline led by NB1111, a THC prodrug for glaucoma, and novel CBD derivatives for retinal diseases and chemotherapy side effects. - Recent milestones include completing a $5M financing, adding experts to their scientific advisory board, partnering with Athyrium to advance programs, and validating NB1111 data showing a 45% reduction in eye pressure. - NEMUS' cannabinoid prodrug programs have a competitive advantage over orally administered cannabinoids, which

1. Investor
Presenta,on
2016
NEMUS
Bioscience
OTCQB:
NMUS

2. 2
Forward
Looking
Statement
This
presenta-on
contains
“forward-­‐looking
statements”
within
the
meaning
of
the
“safe
harbor”
provisions
of
the
Private
Securi-es
Li-ga-on
Reform
Act
of
1995.
All
of
the
statements
in
this
presenta-on,
whether
wriGen
or
oral,
that
refer
to
expected
or
an-cipated
future
ac-ons
and
results
of
NEMUS
Bioscience,
Inc.
(NEMUS)
are
forward-­‐looking
statements.
These
forward-­‐looking
statements
reflect
the
beliefs
and
expecta-ons
of
the
management
of
NEMUS
as
of
the
date
of
this
presenta-on.
NEMUS
cannot
give
any
assurance
that
such
forward-­‐
looking
statements
will
prove
to
be
correct.
The
reader
is
cau-oned
not
to
place
undue
reliance
on
these
forward-­‐
looking
statements.
The
informa-on
provided
in
this
presenta-on
does
not
iden-fy
or
include
any
risk
or
exposures,
of
NEMUS
that
would
materially
adversely
affect
the
performance
or
risk
of
the
company.
For
a
descrip-on
of
the
risks
and
uncertain-es
related
to
the
business
of
NEMUS,
see
our
Annual
Report
on
Form
10-­‐K
for
the
year
ended
December
31,
2014
filed
with
the
Securi-es
and
Exchange
Commission
on
March
27,
2015
and
our
subsequent
periodic
reports
filed
with
the
Securi-es
and
Exchange
Commission.
All
informa-on
contained
in
this
presenta-on
is
provided
as
of
the
date
of
the
presenta-on
and
is
subject
to
change
without
no-ce.
Neither
NEMUS,
nor
any
other
person
undertakes
any
obliga-on
to
update
or
revise
publicly
any
of
the
forward-­‐looking
statements
set
out
herein,
whether
as
a
result
of
new
informa-on,
future
events
or
otherwise,
except
as
required
by
law.
This
presenta-on
does
not
convey
an
offer
of
any
type
and
is
not
intended
to
be,
and
should
not
be
construed
as,
an
offer
to
sell,
or
the
solicita-on
of
an
offer
to
buy,
any
securi-es
of
NEMUS.

3. 3
OTCQB
NMUS
Price
(12/31/15)
$0.70
Market
Cap
(12/31/15)
$12.65
M
Shares
Outstanding
19.3
M
common
&
5000
PS,
25.5
M
if
100%
converted
%
Ownership
by
Directors
&
Employees
28.0%
shares
1.2
M
op-ons
Warrants
Outstanding
10.9
M
(Avg.
Strike
@
$1.15)
Founded
2012
Base
of
Opera-ons
Costa
Mesa,
California
&
Oxford,
Mississippi
Company
Overview
NEMUS
Bioscience
is
a
publicly
traded,
life-­‐science
biotech
company,
developing
regulatory-­‐approved,
cannabinoid-­‐based
therapies,
for
a
spectrum
of
diseases,
especially
those
of
unmet
medical
need

4. 4
NEMUS
Value
Proposi,on
• Proprietary
product
pipeline
led
by
a
pro-­‐drug
of
tetrahydrocannibinol
(THC)
and
novel
deriva-ves
of
cannabidiol
(CBD)
• Poten-al
ophthalmology
franchise:
lead
compound,
NB1111
(prodrug
of
THC)
is
a
first-­‐in-­‐
class
treatment
for
glaucoma;
CBD
deriva-ves
to
be
developed
for
diseases
of
the
re-na
• NEMUS
cannabinoid
compounds
in
development
for
management
of
pallia-ve
care
issues
in
cancer
chemotherapy:
management
of
nausea
&
vomi-ng
(CINV)
and
allevia-on
of
chemotherapy-­‐related
neuropathy
(CIPN)
• An--­‐infec-ve
program
developing
mul-ple
cannabinoid
deriva-ves
for
an--­‐bacterial
poten-al
especially
against
resistant
strains
such
as
MRSA
• The
University
of
Mississippi
(UM)
is
the
only
U.S.
en-ty
authorized
by
the
Federal
government
to
cul-vate
cannabis
for
cannabinoid
research
&
NEMUS
is
the
only
global
partner
of
UM
for
discovery
and
commercializa-on
of
cannabinoid-­‐based
medicines
• NEMUS
management
team
has
proven
track-­‐record
in
drug
research,
pharmaceu-cal
&
biotech
development,
and
public
company
experience
on
a
global
scale

5. 5
Recent
Milestones
• August,
2015:
Comple-on
of
Series
B
$5
million
financing
round
• September,
2015:
global
glaucoma
expert
Dr.
Robert
N.
Weinreb
joins
NEMUS
Scien-fic
Advisory
Board
• October,
2015:
NEMUS
partners
with
Atheln
to
advance
mul-ple
development
programs
• October,
2015:
Patent
issued
in
Japan
for
NB1111
(THC
prodrug)
• December,
2015:
NEMUS
in-­‐licenses
CBD
deriva-ves
from
UM
and
ini-ates
research
into
chemotherapy
induced
periphernal
neuropathy
(CIPN)
• January,
2016:
interna-onally
recognized
cancer
expert
Dr.
Donald
I.
Abrams
joins
NEMUS
Scien-fic
Advisory
Board
• January,
2016:
NEMUS
announces
valida-on
of
NB1111
data
in
glaucoma
with
45%
decline
in
IOP
• January,
2016:
NEMUS
announces
ini-a-on
of
development
program
for
chemotherapy-­‐
induced
nausea
and
vomi-ng
(CINV)
and
pre-­‐NDA
mee-ng
with
the
FDA

6. 6
NEMUS
cannabinoid
prodrug
programs
hold
compe,,ve
advantage
Orally
administered
cannabinoids
(both
pill
and
spray
delivery
mechanisms)
hold
a
variety
of
disadvantages
for
pa,ents
:
• Poor
bioavailability
vs
other
routes
of
administra,on
• Irregular
pharmacokine,cs
secondary
to
GI
absorp,on
• Suscep,ble
to
significant
first-­‐pass
metabolism
by
the
liver
– “Due
to
extensive
first-­‐pass
metabolism
and
high
lipid
solubility,
a
frac-on
of
the
drug
reaches
the
circula-on”1
– “The
pharmacologic
effects
of
Marinol
are
dose-­‐related
and
subject
to
considerable
inter-­‐pa-ent
variability”1
– “Intoxica-on
type
reac-ons
appear
dose-­‐related
due
to
great
inter-­‐pa-ent
drug
level
variability”
2
– “The
pharmacokine-c
data
show
great
inter-­‐subject
variability”3
1) Marinol
Summary
Basis
of
Approval
2) Sa6vex
Product
Labelling
-­‐
Black
Box
Warning
3) Sa6vex
Product
Labelling
NEMUS
prodrug
technology
designed
to
capitalize
on
the
use
of
proprietary
formula,ons
that
could
allow
for
alterna,ve
delivery
methods
mi,ga,ng
risk
of
unpredictable
plasma
levels
that
can
compromise
safety
and
efficacy

7. 7
Innova,ve
Cannabinoid
Formula,ons
Designed
for
Improved
Drug
Delivery
-­‐
• Ocular
delivery:
Glaucoma
&
re-nal
diseases
• Transmucosal
delivery:
CINV
&
CIPN
(suppository
&
buccal
patch)
• Transmembranous
delivery:
An--­‐infec-ves
(An--­‐MRSA)
(nasal/transdermal)
All
NEMUS
licensed
delivery
op,ons
op,mize
our
prodrug
cannabinoid
technology
by
enhancing
bioavailability
by
avoiding
first-­‐pass
liver
metabolism
and
offering
more
predictable
pharmacokine,cs

8. 8
• The
University
of
Mississippi
(UM)
is
the
only
en,ty
in
the
US
authorized
by
NIDA
and
the
DEA
to
cul-vate
cannabis
on
behalf
of
the
federal
government
• The
University
of
Mississippi
has
a
con-nuous
45+
year
regulatory
history
in
dealing
with
FDA,
DEA,
NIDA,
NIH,
etc.
• NEMUS
has
exclusive,
perpetual,
worldwide
exclusivity
for
all
compounds
and
targets
we
are
working
on
with
UM
for
key
fields
of
delivery
• NEMUS
has:
• Recurring
op,on
agreements
for
unique
THC
and
CBD
deriva,ve
molecules
including
patent
8,809,261
issued
August,
2014
covering
NCE
of
cannabinoid
prodrug
esters
• Mul,ple
method
of
delivery
agreements
including
ocular,
transmembranous,
transmucosal
• Mul,ple
research
agreements
including
CIPN
and
MRSA
The
Only
Federally-­‐Approved
Source
of
Cannabis-­‐Derived
Compounds

9. 9
Development
Pipeline:
Op,mizing
THC
and
CBD
delivery
through
unique
formula,ons
Drug
Name
Target
Delivery
Research
Pre-­‐clinical
Phase
1
Phase
2/3
NB1222
(THC-­‐based)
Chemotherapy-­‐
induced
nausea
&
vomi,ng
(CINV)
Suppository
&
Buccal
Patch
NB1111
(THC-­‐based)
Glaucoma/
Ophthalmology
Targets
Sustained
Ocular
ID
pending
(CBD-­‐based)
Chemotherapy-­‐
indUced
peripheral
neuropathy
(CIPN)
Trans-­‐
membranous
ID
pending
Methicillin-­‐Resistant
Staph
Aureus
(MRSA)
Topical
&
Transdermal
Target
indica,ons
are
mul,-­‐billion
dollar
global
markets
of
urgent
medical
need

10. 10
NEMUS
DEVELOPMENT
PROGRAMS
CHEMOTHERAPY-­‐INDUCED
NAUSEA/VOMITING
(CINV)
NB1222
PRODRUG
OF
THC

11. 11
CHEMOTHERAPY-­‐INDUCED
NAUSEA/VOMITING
(CIVN)
• There
are
an
es-mated
15
million
cancer
cases
globally
according
to
the
Interna-onal
Agency
for
Research
on
Cancer
•
25%-­‐30%
of
pa-ents
receive
chemotherapy;
of
the
chemotherapy
recipients,
70%-­‐80%
experience
CINV
• The
global
CINV
market
exceeds
$1.3
B
• Dronabinol
is
an
orally
administered
synthe-c
version
of
THC
approved
for
cachexia
in
HIV
and
nausea/vomi-ng
in
CINV
with
annual
sales
for
CINV
in
excess
of
$110
MM
(Source:
IMS
Health)
• NEMUS
plans
to
develop
a
suppository
version
of
our
proprietary
prodrug
of
THC,
NB
1222,
for
use
in
CINV
by
filing
an
NDA
via
the
expedited
regulatory
pathway
of
505(b)(2)

12. 12
NB1222
advantages
versus
dronabinol
in
CINV
-­‐1
4
9
PD
1
3
5
7
9
11
13
15
17
19
21
23
Plasma
Concentra,ons
(ng/
ml)
Timepoint
(h)
A
Comparison
of
THC
Plasma
Concentra,ons
From
ProDrug
THC
Suppository*
vs.
dronabinol
in
Humans
Dronabinol
10
mg
THC
10
mgEg
• Bioavailability:
Dronabinol
has
been
found
to
have
a
bioavailability
of
6%-­‐15%
while
a
prodrug
of
THC
administered
via
suppository
yielded
a
bioavailability
of
roughly
70%*
• Absorp,on:
Orally
administered
dronabinol
can
have
erra-c
absorp-on
from
the
gut
coupled
to
varying
plasma
levels
due
to
first-­‐pass
metabolism
in
the
liver;
a
suppository
avoids
the
upper
GI
tract
and
thereby
de-­‐risks
the
nega-ve
effect
of
first-­‐pass
metabolism
on
the
drug
pharmacokine-cs
• Adverse
Events:
Oral
dronabinol
has
been
associated
with
nausea
and
vomi-ng
adverse
events;
a
suppository
route
of
administra-on
mi-gates
that
side
effect
• Pharmacokine,cs:
THC
prodrug
dosing
using
a
suppository
allows
greater
drug
exposure
(graph
above)
and
maintenance
within
the
therapeu-c
window
versus
peak/
trough
PK
with
oral
dosing
Source:
NEMUS
Internal
Data

13. 13
GLAUCOMA
NB1111
PRODRUG
OF
THC

14. 14
Visual
Field
Defect
in
Glaucoma
14
How
the
world
is
seen
with
glaucoma

15. 15
The
Glaucoma
Market
• $8
billion
globally
and
growing
with
aging
popula-ons
• A
leading
cause
of
blindness
in
the
US
• $2.3
billion
US
market
(32
MM
Rx)
• Regulatory
pathway
well-­‐defined
• Regulatory
strategy:
Poten-al
for
“urgent
medical
need”
and
“breakthrough
therapy”
FDA
designa-ons;
• Glaucoma
as
a
“Non-­‐responder”
market
presents
greater
opportuni-es;
>50%
of
pa-ents
on
2
or
more
Rx
• Cannabinoids
have
shown
neuroprotec-ve
quali-es
in
vitro
and
in
vivo
(mul-ple
animal
species)
• Licensing
and
acquisi-ons
in
the
glaucoma
market
occur
predominantly
earlier
in
development
(pre-­‐clin,
phase
1)

16. 16
NB1111
(Glaucoma/Ophthalmology)
Sustained
release
treatment
with
a
proprietary
THC
prodrug
could
bring
a
new
therapeu,c
class
directly
to
the
target
organ,
avoiding
systemic
exposure
OCULAR
FEATURES
OF
NB1111
• Penetrates
all
chambers
of
the
eye
• Produces
a
45%
reduc-on
in
Intra-­‐Ocular
Pressure
(IOP)
in
glaucoma
animal
model
(THC
has
been
shown
to
lower
IOP
in
previous
human
tes-ng)
• Reduc-on
of
IOP
is
the
only
proven
method
to
treat
glaucoma
• Sustained
release
via
implantable
delivery
vehicle
enhance
compliance
• Poten-ally
first
medica-on
to
exert
direct
neuroprotec-on
of
the
op-c
nerve
(re-nal
ganglion
cells;
RGCs)
by
inhibi-ng
apoptosis
pathway
• Neuroprotec-on
is
the
“holy
grail”
of
glaucoma
The
proprietary
formula,on
allows
THC
to
be
absorbed
across
membranes
that
are
normally
barriers
to
absorp,on.

17. 17
Cannabinoids
can
address
mul,ple
MOAs
Therapy
Class
Mechanism
of
Ac-on
(MOA)
Increased
flow
Trabecular
mesh
Increased
flow
uveoscleral
pathway
Decreased
fluid
produc-on
Direct
neuroprotec-ve
quali-es
Prostaglandins
(50%
mkt
share)
X
β-­‐
adrenergic
blockers
(30%)
X
α-­‐
adrenergic
agonists
(10%)
X
X
Carbonic
anhydrase
inhibitors
(<5%)
X
Cholinergic
agonists
(<5%)
X
Pro-­‐drug
THC
(NB1111)
X
X
X
X

18. 18
THC
lowers
IOP
in
humans;
predic,ve
animal
model
consistent
with
human
experience
• The
ac-ve
moiety
of
NB1111,
THC,
has
been
shown
to
lower
IOP
in
mul-ple
human
studies
• THC
delivered
by
inhala-on
(smoking)
or
edible
lowered
IOP
40%
to
65%
but
compromises
blood
flow
to
re-na
via
systemic
vasodila-on
and
dosing
complicated
by
short-­‐half
• The
NEMUS
prodrug
NB1111
achieved
a
45%-­‐50%
reduc-on
in
IOP
in
validated
rabbit
glaucoma
model
tes-ng
conducted
at
UM
• New
formula-on
tes-ng
of
NB1111
will
confront
the
compliance
issue
of
topical
drops
(eyedrops)
by
development
of
implantable
sustained
release
device
• Next
stage
tes-ng:
• canine/primate
studies
looking
at
IOP
lowering
effect
as
single
dose
and
mul--­‐dose
via
implantable
device
• In
vitro
and
in
vivo
studies
assessing
neuroprotec-ve
biomarkers

19. 19
Unlike
many
licensing
deals,
ophthamology
deals
are
oien
done
early
in
development
(Discovery
to
Ph
1)
0
10
20
30
40
50
60
70
80
Filed/Appvd
Phase III
Phase II
Phase I
Preclinical
Lead molecule
Discovery stage
(re) formulation
Ophthalmology
deals
Related
to
Pharmaceu,cals
n=265
2007-­‐2014
Acq/purchase
License
Of 408 deals related to ophthalmology revealed in SEC documents, 265 were
related to pharmaceuticals, from early to late stage.

20. 20
CHEMOTHERAPY-­‐INDUCED
PERIPHERAL
NEUROPATHY
CBD
DERIVATIVES

21. 21
CIPN:
Market
Data
• CIPN
is
a
dose-­‐dependent
complica-on
associated
with
many
types
of
chemotherapeu-c
agents
• In
addi-on
to
severe,
some-mes
unremiwng
pain,
it
can
also
lead
to
premature
discon-nua-on
of
chemotherapy
which
in
turn
can
compromise
responses
to
cancer
treatment
• No
agents
have
been
shown
to
prevent
CIPN
and
currently
there
is
a
significant
unmet
medical
need
for
therapies
that
can
mi-gate
the
pain
without
complica-ons
associated
with
addic-on
and
gastrointes-nal
obstruc-on
• The
CIPN
market
in
the
United
States
exceeds
$500
MM
(LifeSci
Advisors,
2013)
and
the
parallel
opioid-­‐induced
cons-pa-on
market
is
es-mated
to
be
$600
MM
globally
(GlobalData,
2015)

22. 22
CIPN:
Next
Steps
• NEMUS
has
signed
a
research
agreement
with
UM
to
test
CBD-­‐related
deriva-ves
in
validated
animal
models
of
CIPN
• NEMUS
expects
to
complete
proof-­‐of-­‐concept
in
vivo
and
in
vitro
tes-ng
in
2016
with
basic
science
data
presented
at
appropriate
scien-fic
mee-ngs
• In
H2’16,
NEMUS
expects
to
begin
formula-on
assessments
to
priori-ze
poten-al
routes
of
delivery
for
the
CBD-­‐based
drug
• Based
on
that
data,
NEMUS
will
decide
to
move
forward
with
a
pre-­‐IND
mee-ng
with
the
FDA
in
H1’2017

23. 23
METHICILLIN-­‐RESISTANT
STAPHYLOCOCCUS
AUREUS
MULTIPLE
CANNABINOID
DERIVATIVES

24. 24
MRSA
has
become
a
global
urgent
health
concern

25. 25
Methicillan-­‐Resistant
Staph
Aureus
(MRSA)
MRSA
FACTS
&
CURRENT
MEDICAL
LANDSCAPE
• First
described
in
1961
now
a
pandemic
• CDC:
prevalence
of
MRSA
in
ICU
sewng
approaching
60%
• 1960’s:
one
gene-c
MRSA
muta-on/clone;
currently
six
MRSA
gene-c
clones;
15
clones
in
China
• 2010
hospital
survey:
61.8%
of
pa-ents
admiGed
to
ICU
were
MRSA
colonized1
• 50%
of
screened
pa-ents
had
healthcare-­‐associated
infec-ons1
• 11,000
deaths
annually;
80,000
invasive
infec-ons/yr.2
• Annual
costs
in
the
US:
$3.2
-­‐
$4
billion2
1) Jarvis
WR
et
al;
Am
J
Infect
Control
2012;
40(3):
194-­‐200
2) Pew
Trust
MRSA
Survey;
April
3,
2012

26. 26
Methicillan-­‐Resistant
Staph
Aureus
(MRSA)
NEMUS
is
assessing
a
new
class
of
an,-­‐infec,ves
to
combat
the
threat
of
an,bio,c
resistance
CANNABINOID
EXPERIENCE
IN
MRSA1
• Select
cannabinoids
have
been
known
to
possess
some
an-bacterial
proper-es
1
• An--­‐bacterial
proper-es
can
be
leveraged
to
address
newly
developed
strains
exhibi-ng
an-bio-c
resistance
to
current
meds
• NEMUS
intends
to
file
IP
concerning
the
use
of
transmembrane
enhancing
formula-ons
of
cannabinoids
to
facilitate
bacteriocidal
ac-vity
• A
spectrum
of
gram-­‐posi-ve
organisms
will
be
screened
in
addi-on
to
MRSA
1) J
Nat
Prod.
2008
Aug;71(8):1427-­‐30.
doi:
10.1021/np8002673.
Epub
2008
Aug
6.
-­‐
An-bacterial
cannabinoids
from
Cannabis
sa-va:
a
structure-­‐ac-vity
study

27. 27
Upcoming
inflec,on
point
,melines
2016
Developmental
Milestones
H1-­‐2016
• Contract
API
manufacturer
for
THC-­‐val-­‐HS
• Ini-ate
2yr
stability
study
API
• Ini-ate
in
vivo
MRSA
studies
• Ini-ate
CIPN
in
vivo
studies
• Complete
ini-al
canine/
primate
study
• Hold
FDA
pre-­‐NDA
mtg
NB1222
(CINV)
• Hold
FDA
pre-­‐IND
mtg
NB1111
(Glaucoma)
H2-­‐2016
• Ini-ate
primate
sustained
release
glaucoma
study:
NB1111
• Ini-ate
IND
enabling
studies
NB1111
• Complete
MRSA
in
vivo
studies
• Ini-ate
MRSA
tox
studies
• Ini-ate
CINV
tox
bridging
studies:
NB1222
• Ini-ate
human
BA-­‐PK
study
in
CINV
• Ini-ate
formula-on
work
on
new
CBD
formula-on
for
CIPN
• Ini-ate
development
of
delivery
system
for
CIPN

28. 28
NEMUS
Bioscience,
Inc.
(OTCQB:
NMUS)
• NEMUS
develops
cannabinoid
molecules
for
the
treatment
and
management
of
acute
and
chronic
diseases,
especially
those
of
unmet
medical
need
• NEMUS
cannabinoid
molecules
are
engineered
to
enhance
trans-­‐membrane
transport
resul-ng
in:
• Enhanced
bioavailability
• Permits
routes
of
administra-on
that
avoid
first-­‐pass
metabolism
by
the
liver
• Resul-ng
in
more
predictable
pharmacokine-cs
• Patent
issued
in
August,
2014
allows
long
IP
runway
with
broad
claims
and
reach
for
the
delivery
of
molecules
and
condi-ons
that
can
be
treated
• NEMUS
is
the
sole
research
and
commercializa-on
partner
of
the
University
of
Mississippi,
drawing
on
47
years
of
intellectual
capital
in
cannabinoid
chemistry
and
physiology
• NEMUS
is
advancing
therapeu-cs
for
medical
applica-ons
in
global
mul--­‐billion
dollar
markets
including
a
cannabinoid
franchise
in
ophthalmology,
pallia-ve
care
in
oncology,
and
an--­‐infec-ve
medicines,
especially
in
strains
developing
resistance
to
an-bio-cs.

29. 29
Management
BRIAN
MURPHY,
MD,
MPH,
MBA
–
Chief
Execu,ve
Officer;
Chief
Medical
Officer,
Director
Dr.
Murphy
has
almost
two
decades
of
experience
in
drug
development
and
evalua-on,
both
from
the
academic
and
industry
perspec-ve.
He
most
recently
served
as
the
CMO
of
Eiger
Biosciences.
Previously,
Dr.
Murphy
was
CMO
at
Valeant
Pharmaceu-cals
Interna-onal
(VRX)
where
his
responsibili-es
also
included
oversight
of
Global
Medical
Affairs
and
Pharmacovigilance.
Dr.
Murphy
also
served
as
Medical
Director,
then
VP
of
Marke-ng
and
Commercial
Strategy
of
Hepatology
for
InterMune,
Inc.
(ITMN).
Prior
to
InterMune,
Dr.
Murphy
was
Medical
Director
of
North
America
for
An-virals/Interferons
at
Hoffmann-­‐LaRoche.
Murphy
is
board-­‐cer-fied
in
internal
medicine
and
completed
his
residency
at
Tuys-­‐New
England
Medical
Center.
He
went
on
to
complete
parallel
fellowship
tracts
at
Harvard
Medical
School
and
the
MassachuseGs
General
Hospital.
Dr.
Murphy
earned
his
MD,
MPH
(general
public
health),
and
MS
(pharmacology)
degrees
from
New
York
Medical
College
and
is
a
graduate
of
the
Harvard
School
of
Public
Health
(MPH
in
Health
Policy
and
Management).
He
earned
his
MBA
at
the
Columbia
University
Graduate
School
of
Business.
LIZ
BERECZ,
MA,
CPA
-­‐
Chief
Financial
Officer
Elizabeth
Berecz
is
a
seasoned
financial
execu-ve
with
over
20
years
of
experience
holding
senior
level
posi-ons
in
both
private
and
public
companies.
She
has
proven
success
in
leading
strategic
planning,
financial
repor-ng,
and
global
system
implementa-ons
for
companies
of
various
sizes.
Liz
started
her
career
at
Price
Waterhouse
Silicon
Valley
where
she
spent
five
years
audi-ng
several
high
profile
public
companies
in
the
technology
industry.
She
then
spent
10
years
holding
key
leadership
posi-ons
in
various
publicly
held
Companies
including
Quantum
Corpora-on
(Corporate
Controller),
Business
Objects
(VP
Finance
and
Administra-on),
and
Excite
(VP
Finance),
followed
by
10
years
of
key
leadership
roles
in
privately
held
Companies
including
CFO
posi-ons
with
Op-cal
Shop
Interna-onal,
StarTrac
Inc.,
Power
Balance
Technologies,
Inc.
and
most
recently
Bentley
Mills,
Inc.
She
also
serves
as
an
Adjunct
Professor
of
Accoun-ng
and
Finance
at
the
University
of
San
Francisco.
Elizabeth
received
her
BA
in
Economics
from
Stanford
University
and
a
MA
in
Sports
Management
from
University
of
San
Francisco.

30. 30
Management
COSMAS
N.
LYKOS,
ESQ
–
Co-­‐founder,
Officer
&
Board
Member
–
Execu,ve
Chairman
Cosmas
Lykos
co-­‐founded
NEMUS
in
2012
and
has
served
as
its
Chairman
of
the
Board
of
Directors
since
August
2014.
Ayer
gradua-ng
with
Honors
from
Duke
University
School
of
Law
in
1993,
Mr.
Lykos
began
his
career
at
Gibson
Dunn
&
Crutcher,
LLP,
an
interna-onal
full-­‐service
law
firm,
as
a
corporate
associate
un-l
1998.
From
1998
to
2004,
Mr.
Lykos
served
as
Vice
President
of
Business
Affairs,
General
Counsel,
Secretary
and
Chief
Compliance
Officer
of
RemedyTemp,
Inc.,
a
NASDAQ
publicly-­‐traded
temporary
staffing
firm
with
over
250
directly-­‐owned
and
franchised
offices
na-onwide.
From
2004
un-l
2008,
Mr.
Lykos
served
as
Vice
President
of
Business
Development,
Chief
Legal
Officer,
Secretary
and
Chief
Compliance
Officer
of
Oakley,
Inc.,
a
NYSE
publicly-­‐traded
sports
and
technical
eyewear,
apparel,
accessories
and
retail
company.
In
January
of
2008,
he
became
Co-­‐owner
and
President
of
the
Op-cal
Shop
Interna-onal,
a
designer
and
distributor
of
licensed
eyewear
brands,
including
Chrome
Hearts
and
Blinde,
through
two
wholly-­‐owned
foreign
subsidiaries
with
a
direct
and
distributor
sales
network
in
over
60
countries
around
the
world.
Primary
responsibili-es
included
developing
and
implemen-ng
OSI’s
vision
and
strategies
and
the
management
of
its
foreign
subsidiaries,
sales,
legal,
human
resources,
finance
and
administra-ve
func-ons.
In
2011,
Mr.
Lykos
nego-ated
and
consummated
the
sale
of
OSI
to
its
primary
licensor,
Chrome
Hearts
LLC
and
con-nues
to
provide
consul-ng
services.
Mr.
Lykos
has
extensive
public
and
private
company
board
of
directors
experience.
As
Chief
Compliance
and
Legal
Officer
and
Secretary
of
both
Oakley,
Inc.
and
RemedyTemp,
Inc.,
Mr.
Lykos
aGended
all
board
of
director
mee-ngs
and
board
commiGee
mee-ngs.
As
an
angel
investor,
Mr.
Lykos
has
made
minority
investments
in
various
private
companies
and
has
served
on
their
Board
of
Directors.

31. 31
BOD
&
Strategic
Advisors
MAHMOUD
A.
ELSOHLY,
PHD
Scien,fic
Advisor
World’s
foremost
expert
on
the
science
of
cannabinoids.
300+
scien-fic
publica-ons
.
Research
professor
at
The
University
of
Mississippi.
JERRY
MCLAUGHLIN,
MBA
Strategic
Advisor,
Board
of
Directors
-­‐
Member
CEO
of
AgeneBio;
25
year
veteran
execu-ve
in
pharmaceu-cal
medical
device
and
healthcare
related
industries
(Endo
Pharma,
Merck,
MBA-­‐
Villanova
University,BA-­‐
Dickinson
College).
TOM
GEORGE
Board
of
Directors
–
Chairman
of
Audit
Commiqee
30
year
senior
execu-ve
in
corporate
finance
and
accoun-ng;
CFO
of
Deckers
Brands
(
Ophthonix,
Oakley,
Coopers
&
Lybrand).
Graduate
of
University
of
Southern
California.
DOUGLAS
S.
INGRAM,
ESQ
Board
of
Directors
–
Vice
Chairman,
Chairman
of
Compensa,on
Commiqee
25
year
senior
execu-ve
in
healthcare,
Past
President
of
Allergan,
former
AGorney
at
Gibson,
Dunn
&
Crutcher,
LLP.
Summa
cum
laude
and
Order
of
the
Coif
graduate
of
the
Univ.
of
Arizona
school
of
law.
Robert
N.
Weinreb,
M.D.
Scien,fic
Advisor
Chair,
Ophthalmology
Advisory
Board
Globally
recognized
expert
on
glaucoma
and
eye
diseases.
1000+
scien-fic
publica-ons.
Dis-nguished
Professor
of
Ophthalmology;
University
of
California
San
Diego
Donald
I.
Abrams,
M.D.
Scien,fic
Advisor
Chief,
Hematology/Oncology
at
UCSF
Cancer
and
Integra,ve
Medicine
specialist
with
research
interests
in
the
development
of
an,-­‐cancer
therapeu,cs
and
pallia,ve
care
medicines

32. 32
Contact
650
Town
Center
Drive,
Suite
1770
Costa
Mesa,
CA
92626
(949)
396-­‐0330
hello@nemusbio.com
www.nemusbioscience.com
Investor
Rela,ons:
Adam
Holdsworth
PCG
Advisory
Group
Tel:
646.862.4607
adamh@pcgadvisory.com
Company
Brian
Murphy,
MD,
MPH,
MBA
CEO
-­‐
CMO
Tel:
949-­‐355-­‐1140
brian@nemusbio.com